Streetbeat News

Analyst Ratings

OLN

UBS analyst Joshua Spector has maintained a Neutral rating on Olin Corporation (NYSE:OLN) and increased the price target from $56 to $58.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 5:04 pm

MTCH

UBS analyst Kunal Madhukar has maintained a Neutral rating on Match Group (NASDAQ:MTCH) and increased the price target from $35 to $38.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 5:03 pm

BPOP

UBS analyst Brock Vandervliet has maintained a Neutral rating on Popular, Inc. (NASDAQ:BPOP) and increased the price target from $84 to $91.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 5:01 pm

VIRT

Citigroup has reaffirmed its Buy rating on Virtu Financial Inc (NASDAQ:VIRT) but reduced its price target from $22.00 to $21.00. Virtu Financial's shares have risen 1.6% in the last 24 hours to $17.74. The new price target suggests an 18.38% upside potential. Virtu Financial is a market maker and liquidity provider, with the majority of its revenue coming from the United States.

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 5:00 pm

NEP

JP Morgan has maintained a Neutral rating for NextEra Energy Partners (NEP) but raised its price target from $24.00 to $26.00. NEP shares are currently trading down at $28.84, which is above the new target. The company, which focuses on contracted clean energy projects and natural gas infrastructure, would see a 9.83% decline in share price if it reached the new target of $26.00.

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 5:00 pm

APPF

AXP

CRBP

EHTH

INTC

PCSA

TKLF

American Express (NYSE:AXP) shares rose over 7% after reporting Q4 financial results and announcing plans to increase its dividend, despite missing revenue and EPS consensus. AppFolio (NASDAQ:APPF) shares surged 28% on strong Q4 results and guidance. Corbus Pharmaceuticals (NASDAQ:CRBP) soared 221% on positive clinical study data. eHealth (NASDAQ:EHTH) gained 24% on preliminary Q4 results. Intel (NASDAQ:INTC) fell 10% due to a weak Q1 forecast. Processa Pharmaceuticals (NASDAQ:PCSA) dropped 25% after announcing a public offering. Yoshitsu (NASDAQ:TKLF) plummeted 60% after a direct offering and private placement announcement. Crude oil was down 1%, while U.S. stocks traded higher overall.

Portfolio Pulse from Avi Kapoor

January 26, 2024 | 5:00 pm

TCBK

Keefe, Bruyette & Woods has maintained its Market Perform rating for TriCo Bancshares (NASDAQ:TCBK) but lowered its price target from $44.00 to $42.00. TriCo's shares are currently trading at $38.27, and the new price target suggests a potential upside of 9.75%. TriCo Bancshares operates as a bank holding company for Tri Counties Bank, offering various banking services primarily in California.

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 5:00 pm

EXPI

DA Davidson has downgraded eXp World Holdings (NASDAQ:EXPI) from a previous rating to Neutral and reduced the price target from $20.00 to $15.00. Following the downgrade, EXPI shares have fallen 3.12% to $13.03. The new price target suggests a potential upside of 15.12% from the current price. eXp World Holdings is a cloud-based residential real estate company with operations in various countries.

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 5:00 pm

BPOP

RBC Capital has reaffirmed its Outperform rating on Popular Inc (NASDAQ:BPOP) and increased its price target from $80.00 to $90.00. Popular's shares are currently trading at $85.83, and the new price target suggests a potential upside of 4.86%. Popular Inc is a financial holding company with significant operations in Puerto Rico and the continental United States.

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 5:00 pm

KRTX

Mizuho has downgraded Karuna Therapeutics (NASDAQ:KRTX) to Neutral, adjusting the price target from $245.00 to $330.00. Despite the downgrade, the new price target suggests a potential upside of 5.05% from the current share price of $314.12. Karuna Therapeutics is a clinical-stage biopharmaceutical company developing therapies for neuropsychiatric conditions.

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 5:00 pm